Saurabh Talke’s Post

𝐃𝐞𝐜𝐨𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: 𝐓𝐡𝐞 𝐑𝐢𝐬𝐞 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 The Global #Cancer_Profiling_Market size is estimated to grow at a CAGR of around 11.5% during the forecast period, i.e., 2024-30. The major factors responsible for the market growth include; the rising prevalence of cancer, increasing research on cancer therapies, and the launch of improved technologies for tumor profiling among others. 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭- https://lnkd.in/g_-6P2wZ 𝐓𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐟𝐨𝐫 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐠𝐫𝐨𝐰𝐭𝐡, 𝐝𝐫𝐢𝐯𝐞𝐧 𝐛𝐲 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐥𝐢𝐤𝐞: ✅ 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐚𝐝𝐨𝐩𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: Cancer profiling helps identify the specific mutations driving a patient's cancer, allowing for targeted treatment options. ✅ 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐨𝐟 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞: Patients are increasingly demanding customized treatment approaches. ✅ 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬: Advancements in genomics and next-generation sequencing (NGS) are making cancer profiling faster and more accurate. Our latest report from MarkNtel Advisors - Market Research Company dives deep into the Cancer Profiling Market, offering:\ ✅ 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 & 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: Understand the current landscape, growth drivers, and trends shaping the market. ✅ 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 & 𝐓𝐫𝐞𝐧𝐝𝐬: Identify key factors influencing market growth and potential areas for investment. ✅ 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐨𝐧𝐬: Gain insights into regional variations and specific markets with high growth potential. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬- NeoGenomics Laboratories, Eurofins Genomics, OncoDNA, 10x Genomics, Caris Life Sciences., Geneseeq Technology Inc., Labcorp, and Others #cancerprofiling #precisionmedicine #healthcare #oncology #marketresearch #marketanalysis #marketresearchreports #marketanalysis #marketgrowth #industryanalysis #industrygrowth #consulting #marknteladvisors

𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 - 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬 & 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 The #Liquid #Biopsy #Market was valued at $2.55 Bn in 2023 and is projected to grow at a CAGR of 20.9% through 2030. This rapid growth underscores the rising importance of liquid biopsy as a non-invasive, cost-effective alternative to traditional cancer diagnosis methods. 𝐅𝐨𝐫 𝐚 𝐝𝐞𝐞𝐩𝐞𝐫 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠, 𝐜𝐥𝐢𝐜𝐤 𝐨𝐧 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤: https://lnkd.in/gkB3V5eF 𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: Technological Advancements: Liquid biopsy offers early cancer detection and personalized treatment by analyzing tumor gene expression profiles without invasive procedures. COVID-19 Impact: The pandemic delayed many cancer diagnostics, increasing the future demand for reliable and fast cancer screening solutions like liquid biopsy. Rising Cancer Incidence: With an estimated 19.3 million new cancer cases globally in 2022, the demand for quick and accurate diagnostic tools like liquid biopsy continues to soar. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬: Drivers: The growing global cancer burden, combined with the advantages of liquid biopsy (early detection, therapy monitoring, lower cost). Restraints: Sensitivity challenges in detecting low levels of circulating tumor DNA (ctDNA). Opportunities: Increasing importance of companion diagnostics in precision medicine. #trend #size #share #growth #demand #analysis #forecast #outlook #industry #LiquidBiopsyMarket #LifeScience

🔬💼 Exciting Insights into the #Liquid #Biopsy #Market! 💼🔬 The Liquid Biopsy Market has been valued at a staggering US$ 2.11 Bn. in 2022, with a projected growth rate of 20.9% CAGR through the forecast period. Dive into key highlights and trends shaping this dynamic sector: 🌟 Overview: Liquid biopsy offers a game-changing approach to cancer detection and treatment, providing a non-invasive, quick, and repeatable sampling technique. With a focus on early detection, therapy response evaluation, and more, it's revolutionizing cancer care. Unlock the full potential of the Liquid Biopsy Market with our in-depth analysis. Request your free sample report now! [https://lnkd.in/dmxvfcGD] 📈 Market Dynamics: Despite challenges posed by COVID-19, the market is poised for growth as cancer remains a global concern. As testing numbers rise post-pandemic, demand for liquid biopsy products is expected to surge. 🚀 Market Drivers: Rising cancer incidence worldwide is propelling the demand for liquid biopsy due to its numerous advantages over conventional methods, including lower costs and early prognosis. 🛑 Market Restraints: Challenges like lower sensitivity of certain liquid biopsies and unclear reimbursement scenarios pose hurdles. However, technological advancements and increasing focus on companion diagnostics offer opportunities for growth. 💡 Market Opportunities: Companion diagnostics are gaining prominence, driving the demand for liquid biopsies. Advancements in technologies like Next-Generation Sequencing (NGS) and the identification of circulating tumor DNA (ctDNA) are expanding possibilities for cancer molecular diagnosis and surveillance. 🌍 Regional Insights: North America leads the market, with the U.S. at the forefront due to higher investments and supportive regulatory frameworks. Canada is also catching up, with government funding driving innovation in liquid biopsy testing. 🔍 Market Analysis: Our comprehensive report provides stakeholders with a clear understanding of the Liquid Biopsy Market, covering past and current trends, market size projections, competitive analysis, and more. It's an essential guide for decision-makers navigating this dynamic industry. #LiquidBiopsy #MarketResearch #CancerDetection #HealthcareInnovation

𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐨𝐧 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐓𝐮𝐦𝐨𝐫 𝐂𝐞𝐥𝐥𝐬 (𝐂𝐓𝐂𝐬) 𝐌𝐚𝐫𝐤𝐞𝐭 The fight against cancer is taking a transformative leap forward with advancements in #Circulating #Tumor #Cell (CTC) #technologies. In 2023, the global market for CTCs reached a valuation of $𝟗.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧, and it’s poised to double to $𝟏𝟗 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, growing at an impressive 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟖.𝟎𝟔% (2024–2032). 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 -https://lnkd.in/gvtE7t7Z Why does this matter? CTCs are revolutionizing cancer diagnostics and treatment, offering a less invasive yet highly precise alternative to traditional biopsies. With their potential to monitor disease progression in real-time, they empower clinicians to personalize therapies and improve patient outcomes. 𝐓𝐨𝐩 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐓𝐮𝐦𝐨𝐫 𝐂𝐞𝐥𝐥𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 Greiner Bio-One International Advanced Cell Diagnostics (ACD) AVIVA Biosciences Biocept, Inc. BioFluidica, Inc. Bio-Techne Fluxion Innovations Menarini Silicon Biosystems Miltenyi Biotec Precision For Medicine QIAGEN Rarecells 𝐎𝐭𝐡𝐞𝐫 𝐏𝐫𝐨𝐦𝐢𝐧𝐞𝐧𝐭 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 This robust growth is fueled by increasing cancer prevalence, a surge in liquid biopsy adoption, and continued investments in research and innovation. As the market evolves, the collaboration between healthcare innovators, biotech firms, and diagnostic companies will be crucial to driving accessibility and affordability. The future of cancer care is here—and it’s evolving faster than ever. #HealthcareInnovation #CancerCare #CirculatingTumorCells #Biotech #Diagnostics #LiquidBiopsy

🌟 Biotech Watchlist: Phase 3 Catalysts to Watch in Q4 2024 🌟 As we near the year's end, fewer than 100 Phase 3 catalysts remain on the horizon, with about 30 expected to release topline data. This week, we spotlight some pivotal programs that could reshape their fields. Cassava Sciences (NASDAQ: SAVA) is advancing simufilam for Alzheimer’s disease. With two Phase 3 trials underway and data expected by Q4 2024, this small molecule therapy could transform care for a population with significant unmet needs. Early data hinted at cognitive benefits, and the latest studies aim to confirm efficacy and safety over a 52-week period. BioCardia (NASDAQ: BCDA) is developing CardiAMP, a breakthrough cell therapy for ischemic heart failure. Phase 3 data due Q4 2024 could validate early findings, including a 37% reduction in heart failure-related mortality. This milestone could pave the way for approval of a therapy addressing critical cardiovascular needs. NovoCure (NASDAQ: NVCR) is exploring Tumor Treating Fields (TTFields) for pancreatic cancer in its PANOVA 3 Phase 3 trial. Results expected in Q4 2024 could expand the utility of TTFields, already approved for other cancer types, offering hope for patients with this difficult-to-treat malignancy. Let’s hear from you! Which of these programs are you watching most closely? What do you think could have the biggest impact? Share your thoughts!👇 #Biotech #Phase3 #DrugDevelopment #Investing #Innovation #Healthcare #FDACalendar #BeThereWhenItHappens #FasterScience #BioPharmCatalyst

𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨 𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐓𝐮𝐦𝐨𝐫 𝐂𝐞𝐥𝐥𝐬 (𝐏𝐃𝐅) 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐆𝐮𝐢𝐝𝐞: https://lnkd.in/dSRGb4_a The Circulating Tumor Cells (CTCs) sector is transforming the landscape of cancer diagnostics and personalized oncology. By enabling real-time insights into tumor biology through non-invasive "liquid biopsies," this market is equipping healthcare providers with critical tools for early detection, monitoring, and treatment customization. 📈 Market Growth: The Circulating Tumor Cells market is forecasted to experience notable expansion, supported by rising cancer incidence rates and increasing focus on early diagnosis and tailored treatment approaches. CTCs hold the potential to significantly enhance precision in cancer care. 🌐 Applications: The impact of CTCs is being felt across key areas in oncology: • Early Detection: Detecting cancer in its nascent stages, enabling timely and targeted interventions. • Treatment Monitoring: Offering insights into the effectiveness of ongoing therapies, allowing for quick adjustments. • Metastasis Tracking: Providing critical data to anticipate and manage metastatic progression in real-time. 🚀 Challenges Ahead: While promising, the CTC market faces hurdles in standardization, regulatory compliance, and clinical adoption. Yet, with continued technological advancements and collaboration, CTCs are well-positioned to set new standards in oncology. 💡 Key Players: QIAGEN; Bio-Techne; Precision For Medicine; AVIVA Biosciences; Biocept, Inc. ; BioCep; Fluxion Biosciences, Inc.; Greiner Bio-One International; Ikonisys; Miltenyi Biotec; IVDiagnostics, Inc.; BioFluidica, Inc.; Canopus Bioscience Ltd.; Biolidics Limited (Formerly known as Clearbridge BioMedics); Creativ MicroTech, Inc.; LungLife AI; Epic Sciences; Rarecells ; ScreenCell; Menarini Silicon Biosystems; LineaRx, Inc. (Vitatex, Inc.); Sysmex Corporation; STEMCELL Technologies #Oncology #CancerResearch #PrecisionMedicine #CirculatingTumorCells #LiquidBiopsy #CancerDiagnostics #PatientCare #HealthcareInnovation #BioTech #CTC #HealthTech #EarlyDetection #PersonalizedMedicine #CancerAwareness #TumorTracking

OncoDxRx bringing equity and accessibility to precision medicine Cancer is a network-based disease driven by many interconnected components, but current machine learning and training models for predicting treatment responses don’t always reflect this. Rather than focusing on a few tumor genes or proteins, OncoDxRx’s PGA technology evaluates the broader biochemical networks or pathways, both tumor and non-tumor microenvironment, vital for cancer killing. The concept of having PGA at the same time of diagnosis will benefit many people, not only in terms of speed and time to get them on the right frontline therapy but also for personal management. A woman who was recently diagnosed with triple-negative breast cancer must wait three weeks and spend thousands to find out how she will be treated. That has to be extremely painful. The work on PGA has significant implications regarding the equity of precision medicine. After all, not many people or insurance companies like paying $3,000 for a test to determine what therapy to prescribe and with the luck of only one out of five (20-30% chance to be qualified). Instead of paying thousands of dollars and waiting weeks for a NGS-based biomarker test right off the bat, PGA can provide the relevant decision-making in 5 days with much less cost, that should eliminate financial and the painful waiting time. Just as NGS biomarker testing has evolved, where we sequence every patient because we want that information for responder identification, we will also use PGA for every solid tumor case because we will want this therapeutic information for non-responders as well. It’s going to become a standard. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing